A1C Reductions and Improved Patient-Reported Outcomes Following CGM Initiation in Insulin-Managed T2D
At the American Diabetes Association 80th Scientific Sessions, researchers from Dexcom presented the latest findings on a study of the Dexcom G6 Continuous Glucose Monitoring (CGM) System. The research looked at glycemic and quality of life indicators for a cohort of 39 commercially insured adults with T2D (age 25-65)* who were managed with intensive insulin therapy and used CGM for at least 12 weeks. Watch the five-minute poster presentation below.
Related Content
Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study Anagha Champakanath, Halis Kaan Akturk, G...
The efficacy and safety of the Control-IQ hybrid closed-loop system, powered by Dexcom G6, was evaluated in a multi-centered, randomized, and unblinded study.1 The researchers randomized 168...